Announcements Trials
Browse Landscape

Phase

Phase 2 45Phase 1 21Phase 3 19Phase 1/2 13Phase NA 3Phase 4 2

Status

Not yet recruiting 4Unknown 2Completed 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Gastrointestinal 1

Conditions

Thyroid Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Zoledronic Acid 28Saline Solution 26Metformin 25Dexamethasone 25Cyclophosphamide 23Cytarabine 22Bupivacaine 20Sodium Chloride 18Vincristine 17Methotrexate 17Letrozole 17Propofol 15Morphine 15Doxorubicin 15Prednisolone 14Docetaxel 14Dexmedetomidine 14Cisplatin 14Bevacizumab 14Oxycodone 13Imiquimod 13Fentanyl 13Capecitabine 13Rituximab 12Mercaptopurine 12Fluorouracil 12Granulocyte Colony-Stimulating Factor 11Everolimus 11Asparaginase 11Acetaminophen 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Completed × lenvatinib × Clear all
NCT03573960 2026-03-06

A Study to Evaluate the Safety and Efficacy of Lenvatinib in Participants With Refractory Differentiated Thyroid Cancer

Eisai Inc.

Phase 4 Completed
50 enrolled
Head & Neck

Thyroid Neoplasms

NCT04297254 2023-11-15

A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC

Eisai Inc.

Phase 4 Completed
50 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡